Oric Pharmaceuticals (ORIC)
(Real Time Quote from BATS)
$8.02 USD
+0.35 (4.56%)
Updated Apr 26, 2024 01:12 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Oric Pharmaceuticals, Inc. [ORIC]
Reports for Purchase
Showing records 1 - 20 ( 53 total )
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Looking Forward to ORIC-944 Results; 4Q23 Financials Reported; Raising PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-944 Movin'' on to Combos; ''114 on Course
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-533 Could Emulate Nirogacestat''s Clinical Path; Modulating PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-533 Looking for Someone Under the Mistletoe
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial ORIC-533 Results Expected at ASH; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Gettin'' Ready to Make a Splash at ASH; Prostate Exam Next Year
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Abstract Round Up for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial ORIC-114 Results Impress, in Our View; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-114 Inserting Into the EGFR/HER2 Landscape
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D